These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 18190706)
1. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Cheng F; McLaughlin PJ; Verderame MF; Zagon IS Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706 [TBL] [Abstract][Full Text] [Related]
2. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cheng F; Zagon IS; Verderame MF; McLaughlin PJ Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995 [TBL] [Abstract][Full Text] [Related]
3. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Cheng F; McLaughlin PJ; Verderame MF; Zagon IS Mol Biol Cell; 2009 Jan; 20(1):319-27. PubMed ID: 18923142 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Zagon IS; Verderame MF; Hankins J; McLaughlin PJ Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915 [TBL] [Abstract][Full Text] [Related]
5. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Donahue RN; McLaughlin PJ; Zagon IS Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547 [TBL] [Abstract][Full Text] [Related]
6. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. Zagon IS; McLaughlin PJ Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893 [TBL] [Abstract][Full Text] [Related]
7. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772 [TBL] [Abstract][Full Text] [Related]
8. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor. McLaughlin PJ; Zagon IS Int J Oncol; 2006 Jun; 28(6):1577-83. PubMed ID: 16685459 [TBL] [Abstract][Full Text] [Related]
9. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606 [TBL] [Abstract][Full Text] [Related]
11. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease. McLaughlin PJ; Zagon IS Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282 [TBL] [Abstract][Full Text] [Related]
12. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Zagon IS; McLaughlin PJ Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586 [TBL] [Abstract][Full Text] [Related]
13. Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking. Cheng F; McLaughlin PJ; Zagon IS Exp Biol Med (Maywood); 2010 Sep; 235(9):1093-101. PubMed ID: 20705629 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. McLaughlin PJ; Verderame MF; Hankins JL; Zagon IS Int J Mol Med; 2007 Mar; 19(3):421-8. PubMed ID: 17273790 [TBL] [Abstract][Full Text] [Related]
15. Expression of the tumor suppressor ARHI inhibits the growth of pancreatic cancer cells by inducing G1 cell cycle arrest. Lu X; Qian J; Yu Y; Yang H; Li J Oncol Rep; 2009 Sep; 22(3):635-40. PubMed ID: 19639215 [TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma. Zagon IS; Smith JP; Conter R; McLaughlin PJ Int J Mol Med; 2000 Jan; 5(1):77-84. PubMed ID: 10601579 [TBL] [Abstract][Full Text] [Related]
17. Differential role of diphenyleneiodonium, a flavoenzyme inhibitor, on p53-dependent and -independent cell cycle progression. Song JD; Kim KM; Kim KH; Kim CD; Kim JM; Yoo YH; Park YC Int J Oncol; 2008 Dec; 33(6):1299-306. PubMed ID: 19020764 [TBL] [Abstract][Full Text] [Related]
18. Peripheral-type benzodiazepine receptor overexpression and knockdown in human breast cancer cells indicate its prominent role in tumor cell proliferation. Li W; Hardwick MJ; Rosenthal D; Culty M; Papadopoulos V Biochem Pharmacol; 2007 Feb; 73(4):491-503. PubMed ID: 17126818 [TBL] [Abstract][Full Text] [Related]
19. Involvement of extracellular signal-related kinase signaling in esculetin induced G1 arrest of human leukemia U937 cells. Lee SH; Park C; Jin CY; Kim GY; Moon SK; Hyun JW; Lee WH; Choi BT; Kwon TK; Yoo YH; Choi YH Biomed Pharmacother; 2008 Dec; 62(10):723-9. PubMed ID: 18222060 [TBL] [Abstract][Full Text] [Related]
20. Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells. Moh MC; Zhang T; Lee LH; Shen S Carcinogenesis; 2008 Dec; 29(12):2298-305. PubMed ID: 18845560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]